A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation of our Company

Our Company was incorporated in the PRC on January 24, 2003 under the name of Changsha Aier Eye Hospital Group Limited (長沙愛爾眼科醫院集團有限公司), and was converted into a joint stock limited company on December 5, 2007. Our Company completed the listing of our A Shares on the Shenzhen Stock Exchange (stock code: 300015) on October 30, 2009.

As of the date of this document, our Company's registered address and headquarters are located at Aier Building, 188 Section 1, Furong South Road, Tianxin District, Changsha, the PRC. Our Company's corporate structure and Articles of Association are governed by PRC laws and regulations. The relevant PRC laws and regulations and a summary of the Articles of Association are set out in "Appendix IV — Summary of Principal Laws and Regulatory Provisions" and "Appendix V — Summary of the Articles of Association" to this document, respectively.

Our registered place of business in Hong Kong is at 46/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. We [have registered] as a non-Hong Kong Company under Part 16 of the Companies Ordinance on April 23, 2026. Ms. KWOK Yan Ting Jennis, one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of the service of process on behalf of our Company in Hong Kong. The address for the service of process is the same as our principal place of business in Hong Kong.

2. Changes in the Share Capital of Our Company

On May 27, 2024, the share capital of our Company decreased from RMB9,328,411,413 to RMB9,327,014,495 due to the cancellation of restricted shares under the 2021 Restricted Share Incentive Scheme.

On May 23, 2025, the share capital of our Company decreased from RMB9,327,014,495 to RMB9,325,396,670 due to the repurchase and cancellation restricted shares under the 2021 Restricted Share Incentive Scheme.

Save as disclosed above, there has been no other alteration in the share capital of our Company during the two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

We have applied to the Stock Exchange for, and the Stock Exchange [has granted] us a waiver from strict compliance with the requirements of paragraph 26 of Appendix D1A to the Listing Rules in relation to the disclosure of information relating to the changes in the share capital of any member of our Group within the two years immediately preceding the date of this document. For details, see "Waivers and Exemptions — Waiver and exemption in respect of particulars of information of our subsidiaries" in this document.

The following alterations in the registered capital of our major subsidiaries have taken place within the two years immediately preceding the date of this document:

(1) Beijing Aier Intech Eye Hospital (北京愛爾英智眼科醫院有限公司)

The registered share capital of Beijing Aier Intech Eye Hospital (北京愛爾英智眼科醫院有限公司) was increased from RMB10,000,000 to RMB200,000,000 on August 28, 2024 due to our Company's capital injection.

(2) ISEC Healthcare Ltd. ("ISEC")

On April 2, 2024, the number of issued and paid-up shares in the ISEC was increased from 574,473,912 ordinary shares to 575,193,052 ordinary shares due to exercise of options granted under the ISEC Healthcare Share Option Scheme 2014.

On May 15, 2025, the number of issued and paid-up shares in the ISEC has increased from 575,193,052 ordinary shares to 575,700,552 ordinary shares due to exercise of options granted under the ISEC Healthcare Performance Share Plan 2025.

Save as disclosed above, there has been no change in the share capital of our Major Subsidiaries within the two years immediately preceding the date of this document.

4. Resolutions of Shareholders of Our Company Passed on May 18, 2026

Written resolutions of our Shareholders were passed on May 18, 2026, pursuant to which, among others:

(a) *Size of the* [**REDACTED**]. The proposed number of H Shares to be [**REDACTED**] shall not exceed [**REDACTED**]% of the total issued share capital enlarged by the H Shares to be issued pursuant to the [**REDACTED**] (before the exercise of the [**REDACTED**]). The number of H Shares to be issued pursuant to the full exercise of the [**REDACTED**] shall not exceed [**REDACTED**]% of the total number of H Shares to be [**REDACTED**] initially under the [**REDACTED**].

(b) *Method of* [**REDACTED**]. The method of [**REDACTED**] shall be by way of a [**REDACTED**] [**REDACTED**] for subscription in Hong Kong and an international [**REDACTED**] to institutional [**REDACTED**].

(c) *Target* [**REDACTED**]. The H Shares shall be issued to overseas institutional [**REDACTED**], qualified domestic institutional [**REDACTED**] and other [**REDACTED**] who are approved by Chinese Mainland regulatory bodies to [**REDACTED**] abroad.

(d) [**REDACTED**] *basis.* The [**REDACTED**] Price of the H Shares will be determined by the Board and/or its authorized person with the authorization of the Shareholders' general meetings, together with the [**REDACTED**], after full consideration of the interests of existing Shareholders, the acceptance of [**REDACTED**] and the risks relating to the [**REDACTED**], with reference to the international practices and the prevailing conditions of domestic and international capital markets and through book-building process and cumulative bidding.

(e) *Validity period.* The issue and [**REDACTED**] of H Shares on the Hong Kong Stock Exchange shall be completed within 24 months from the date on which such matters were approved at the Shareholders' meeting held on May 18, 2026. If the Company has obtained approval or filing from relevant regulatory bodies for the issue and [**REDACTED**] of the H Shares within such validity period, the validity period of the resolution will automatically be extended to the completion of the issuance and [**REDACTED**] of the H Shares.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contract

We have entered into the following contract (not being contracts entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(i) the [**REDACTED**].

2. Intellectual Property Rights

(a) Trademarks

Registered Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Owner	Class	Place of Registration	Expiry Date	Registration Number
1. .	爱尔	the Company	44	PRC	October 13, 2033	4200991
2. .	EYƎ	the Company	42	PRC	January 13, 2033	1968005
3. .	爱尔眼科 AIER OPHTHALMOLOGY	the Company	44	PRC	April 6, 2036	3812124
4. .	爱尔眼科 AIER OPHTHALMOLOGY	the Company	44	PRC	August 27, 2035	82093468
5. .	爱尔眼科 AIER OPHTHALMOLOGY	the Company	44	PRC	February 27, 2028	22028693
6. .	Aier 爱尔	the Company	42	PRC	September 6, 2031	1631923
7. .	爱尔	the Company	42	PRC	January 6, 2028	4200990
8. .	爱尔	the Company	9	PRC	January 6, 2027	4200988
9. .	爱尔小熊	the Company	5	PRC	October 6, 2031	40286364
10.	爱尔西柚	the Company	44	PRC	August 27, 2031	52134721
11.	EYƎ	the Company	9	PRC	December 20, 2026	4200834
12.	愉阅	the Company	9	PRC	February 13, 2030	6110934
13.	小青葵	the Company	9	PRC	December 20, 2033	70844851
14.		the Company	44	PRC	April 20, 2035	81384903
15.	Aier 爱尔	the Company	9	PRC	August 20, 2031	1622202
16.	EYƎ 爱尔眼科 AIER EYE HOSPITAL	the Company	44	Hong Kong, China	June 25, 2035	306944851

Trademarks under Application

As of the Latest Practicable Date, we had applied for registration of the following trademark which we consider to be or may be material to our business:

No.	Trademark	Applicant	Class	Place of Application	Application Date	Application Number
1. .	AIER	the Company	44	PRC	November 21, 2024	82109112

No.	Trademark	Applicant	Class	Place of Application	Application Date	Application Number
2. .	EYƎCHO	the Company	42	PRC	November 21, 2024	82105209
3. .	EYƎCHO	the Company	44	PRC	November 21, 2024	82115519
4. .	FEDEYƎ	the Company	42	PRC	October 30, 2023	74856091
5. .	爱尔爱科	the Company	38	PRC	May 20, 2025	85417582
6. .	爱科	the Company	9	PRC	November 21, 2024	82114556
7. .	爱科	the Company	38	PRC	November 21, 2024	82110756
8. .	爱科	the Company	41	PRC	November 21, 2024	82116199
9. .	爱科	the Company	42	PRC	November 21, 2024	82104024
10.	爱科	the Company	44	PRC	November 21, 2024	82099281

(b) Patents

Registered Patents

As of December 31, 2025, we owned the following registered patents which we consider to be or may be material to our business:

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
1. . .	A transscleral continuous drug delivery device for the treatment of eye diseases (一種用於眼部疾病治療的跨鞏膜持續給藥裝置)	Utility model	PRC	ZL2024227996903	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital (愛爾眼科醫院集團股份有限公司長沙愛爾眼科醫院)	November 18, 2034
2. .	Multifunctional medical vision patch for children (兒童醫用多功能視力遮眼罩)	Utility model	PRC	ZL2024220748673	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital	August 26, 2034
3. .	Epiphora Detection Model Construction Method, Epiphora Detection Method, Device, and Apparatus (一種淚溢檢測模型構建方法、淚溢檢測方法、裝置和設備)	Invention	PRC	ZL2024107042935	the Company	June 3, 2044
4. .	A method, apparatus, device and medium for retinal vessel imaging segmentation (一種視網膜血管成像分割方法、裝置、設備及介質)	Invention	PRC	ZL2024106237758	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital	May 20, 2044
5. .	A type of meibomian gland unblocking forceps (一種瞼闆腺疏通鑷)	Utility model	PRC	ZL202322865932X	Guangzhou Aier Eye Hospital Co., Ltd.	October 25, 2033

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
6.	A glaucoma detection device (一種青光眼檢測設備)	Utility model	PRC	ZL2023219718193	Wuhan Aier Eye Hospital Co., Ltd.	July 25, 2033
7.	A method, apparatus, device, and storage medium for ultra-wide-angle fundus image recognition (一種超廣角眼底影像識別方法、裝置、設備及存儲介質)	Invention	PRC	ZL2023107614338	the Company	June 26, 2043
8.	A method, apparatus, device, and readable storage medium for detecting fundus regions (一種眼底區域檢測方法、裝置、設備及可讀存儲介質)	Invention	PRC	ZL2023105248549	the Company	May 11, 2043
9.	A lens and eyeglasses (一種鏡片及眼鏡)	Utility model	PRC	ZL2022217835198	Hunan Aier Institute of Optometry and Vision Science	July 11, 2032
10.	Orthokeratology lens fitting methods, devices, equipment, and readable storage media (角膜塑形鏡配鏡方法、裝置、設備及可讀存儲介質)	Invention	PRC	ZL2021109241836	the Company	August 12, 2031
11.	Application of compound LM22B-10 in the preparation of drugs for the treatment of corneal epithelial and nerve injuries (化合物LM22B-10在製備角膜上皮及神經損傷治療藥物中的應用)	Invention	PRC	ZL2021108575365	the Company	July 28, 2041
12.	A corneal sensory pen (一種角膜知覺筆)	Invention	PRC	ZL2020115002414	Wuhan Aier Eye Hospital Co., Ltd.	December 17, 2040
13.	Corneal endothelial protection device and its main body and attachment parts (角膜內皮保護裝置及其主體部分和附連部分)	Invention	PRC	ZL2020100008028	Beijing Aier Intech Eye Hospital Co., Ltd.	January 2, 2040

Patents under Application

As of December 31, 2025, we have applied for the registration of the following patents which we consider to be or may be material to our business:

No.	Patent Application	Type of Patent	Place of Registration	Patent Number	Applicant	Application Date
1. .	A cataract detection model training method, cataract detection method, and system (一種白內障檢測模型訓練方法、白內障檢測方法和系統)	Invention	PRC	2025109636010	the Company	July 14, 2025
2. .	Nanomedicines for treating eye diseases, their preparation methods, and applications (治療眼部疾病的納米藥物及其製備方法、應用)	Invention	PRC	2025106896923	the Company	May 27, 2025
3. .	A type of adjustable amblyopia treatment glasses (一種可變調節弱視治療眼鏡)	Utility model	PRC	2025209229630	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital, the Company, Hunan Aier Institute of Optometry and Vision Science	May 12, 2025
4. .	A refractive detection system (一種屈光檢測系統)	Invention	PRC	2024118145333	the Company	December 11, 2024
5. .	Ultrasonic biological microscope examination device for ophthalmology and its usage method (用於眼科的超聲生物顯微鏡檢測裝置及其使用方法)	Invention	PRC	2024115829054	Liaoning Aier Eye Hospital Co., Ltd.	November 7, 2024
6. .	An injectable hydrogel long-acting formulation and its preparation method (一種可注射水凝膠長效製劑及其製備方法)	Invention	PRC	2024110118747	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital, the Company	July 26, 2024
7. .	A system, method, device and medium for detecting fungal keratitis (一種真菌性角膜炎檢測系統、方法、設備及介質)	Invention	PRC	2024101978528	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital, the Company, Institute of Computing Technology, Chinese Academy of Sciences	February 22, 2024
8. .	A method and system for quantifying tactile perception information for ophthalmic surgery (一種面向眼科手術的觸覺感知信息量化方法及系統)	Invention	PRC	2023115465937	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital	November 20, 2023

No.	Patent Application	Type of Patent	Place of Registration	Patent Number	Applicant	Application Date
9. .	A federated learning-based disease detection system, method, device, and medium (一種基於聯邦學習的疾病檢測系統、方法、設備及介質)	Invention	PRC	2023111166809	Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital	August 31, 2023
10. .	Model training methods, methods and devices for determining intraocular lens power (模型的訓練方法、人工晶狀體度數確定方法和裝置)	Invention	PRC	2023105316419	the Company	May 12, 2023
11. .	Ophthalmic instruments for measuring the optical quality of the eye (測量眼睛的光學質量的眼科儀器)	Invention	PRC	2022252720	the Company	April 1, 2022

(c) Copyrights

Software Copyrights

As of the Latest Practicable Date, we were the registered proprietor of the following software copyrights which we consider to be or may be material to our business:

No.	Subject	Owner	Certification Number	Place of Registration	First Published Date
1. . .	Aier medical cloud platform (愛爾醫療雲平台)	the Company	2025SR0747060	PRC	N/A
2. . .	Aier eye data intelligence platform (愛爾眼科數據智能平台)	the Company	2025SR1052748	PRC	N/A
3. . .	Aier eye internet hospital system (AOHS System) (愛爾眼科互聯網醫院系統)	the Company	2021SR1209703	PRC	June 10, 2021
4. . .	Aier remote consultation system (愛爾遠程會診系統)	the Company	2025SR0590914	PRC	N/A
5. . .	Aier eye image archiving and communication system (APACS) (愛爾眼科影像歸檔與通信系統)	the Company	2019SR0662019	PRC	Unpublished
6. . .	Aier hospital ADP development platform (ADP) (愛爾醫院ADP開發平台)	the Company	2020SR1265558	PRC	February 25, 2020
7. . .	Aier youth myopia prevention and control system (愛爾青少年近視防控系統)	the Company	2021SR1406024	PRC	Unpublished
8. . .	Aier customer relationship management system (ACRM System) (愛爾客戶關係管理系統)	the Company	2022SR1585691	PRC	July 14, 2021
9. . .	Aier eye supplier portal system (愛爾眼科供應商門戶系統)	the Company	2024SR1538234	PRC	N/A
10. .	Aier Eye Hospital Quality Monitoring System (AHQM) (愛爾眼科醫院質量監測系統)	the Company	2024SR1542211	PRC	N/A

(d) Domain Names

As of the Latest Practicable Date, we had registered the following internet domain names which we consider to be or may be material to our business:

No.	Domain Name	Owner	Expiry date
1. . .	www.aierchina.com	the Company	December 21, 2026
2. . .	www.csu-aso.com	the Company	July 4, 2026
3. . .	www.aieriovs.com	Hunan Aier Optometry and Vision Research Institute	April 15, 2027
4. . .	www.aier-aei.com	Hunan Aier Eye Research Institute	March 12, 2027

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks, patents or other intellectual or industrial property rights which were material in relation to our Group's business.

C. FURTHER INFORMATION ABOUT OUR DIRECTORS, CHIEF EXECUTIVE AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interest

(a) Interests of the Directors and Chief Executive in the Shares of Our Company

The following table sets out the interests of our Directors and chief executive of our Company as of the date of this document and immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised) in the Shares of our Company or any of our associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to us and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers contained in the Listing Rules:

(i) Interest in our Company

			As of the Latest Practical Date(1)		Immediately after the [REDACTED]	
Name	Nature of interest	Description of Shares	Number of Shares	Approximate percentage of interest in our Company	Number of Shares	Approximate percentage of interest in our Company(2)
Mr. CHEN	Beneficial owner	A Shares	1,443,791,891	15.48%	1,443,791,891	[**REDACTED**]%
	Interest in controlled corporation(3)	A Shares	3,202,323,587	34.34%	3,202,323,587	[**REDACTED**]%
	Interest in treasury Shares(4)	A Shares	31,363,178	0.34%	31,363,178	[**REDACTED**]%
Mr. LI	Beneficial owner	A Shares	323,014,994	3.46%	323,014,994	[**REDACTED**]%
Dr. WU Shijun	Beneficial owner	A Shares	2,268,773	0.02%	2,268,773	[**REDACTED**]%
Mr. ZHOU Jianjun . .	Beneficial owner	A Shares	71,697	0.0008%	71,697	[**REDACTED**]%

Notes:

(1) As disclosed in the announcement of the Company dated May 18, 2026 published on the Shenzhen Stock Exchange, the Company proposed to repurchase and cancel 25,831,936 restricted A Shares granted but not yet vested under the 2021 Restricted Share Incentive Scheme. Such repurchase and cancellation is expected to be completed approximately 45 days after the date of such announcement. As such, the share capital of the Company will be RMB9,299,564,734 upon completion of the cancellation.

(2) Assuming (i) the [**REDACTED**] is not exercised and (ii) save for the above-mentioned repurchase and cancellation of 25,831,936 restricted A Shares, no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [**REDACTED**].

(3) Aier Investment is a limited liability company incorporated in the PRC. As of Latest Practicable Date, Mr. CHEN held approximately 79.99% of its shares, while Mr. LI held approximately 20.01%. Accordingly, Mr. CHEN is deemed to be interested in the 3,202,323,587 A Shares held by Aier Investment under the SFO.

(4) As of the Latest Practicable Date, there were 31,363,178 A Shares repurchased and held in our Company's stock repurchase account. Our Controlling Shareholders who control more than one-third of the voting power at the general meetings of our Company would be taken to have an interest in such repurchased A Shares held by our Company.

(b) Interests of the substantial Shareholders in the Shares of our Company

Save as disclosed below and in the section headed "Substantial Shareholders," immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), our Directors are not aware of any other person (not being a Director or chief executive of our Company) who will have an interest or short position in the Shares or the underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the voting power at any general meeting of any member of our Group.

2. Particulars of Service Contracts

Our Company has entered into a service agreement or appointment letter with each of the Directors. The principal particulars of these service agreements and appointment letters are: (a) each of the agreement or letter is for a term of three years following the commencement date of his/her term of office; and (b) each of the agreement or letter is subject to termination in accordance with their respective terms. The service agreements and appointment letters may be renewed in accordance with our Articles of Association and the applicable laws, rules and regulations from time to time.

Save as disclosed above, our Directors have not entered into or propose to enter into any service contracts with any member of our Group (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

3. Directors' Remuneration

Save as disclosed in "Directors and Senior Management" of this document and Note 13 to the Accountant's Report as set out in Appendix I to this document, for the three financial years ended December 31, 2023, 2024 and 2025, none of our Directors received other remunerations of benefits in kind from us.

There were no arrangements under which any Director has waived or agree to waive any emolument during the Track Record Period.

4. Disclaimers

Save as disclosed in this document:

(i) there is no existing or proposed service contract (excluding any contract expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)) between our Directors and any member of our Group;

(ii) none of our Directors or the experts named in the paragraph headed "— E. Other Information — 9. Qualifications and Consents of Experts" in this Appendix has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;

(iii) save in connection with the [**REDACTED**] Agreements, none of our Directors nor any of the experts named in the paragraph headed "— E. Other Information — 9. Qualifications and Consents of Experts" in this Appendix is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group as a whole;

(iv) none of our Directors and the chief executive of our Company has any interests or short positions in the Shares, underlying Shares or debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be entered into the register referred to therein, or will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, to be notified to our Company and the Stock Exchange; and

(v) none of our Directors or their respective close associates or any Shareholders of our Company (who to the knowledge of our Directors owns more than 5% of the number of our issued shares) has any interest in our five largest suppliers or our five largest customers.

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or any of the subsidiaries of our Company.

2. Litigation

As of the Latest Practicable Date, save as disclosed in this document, we were not aware of any other litigation or arbitration proceedings of material importance pending or threatened against us or any of our Directors that would have a material adverse effect on our financial condition or results of operations.

3. The Sole Sponsor

The Sole Sponsor satisfies the independence criteria applicable to sponsor set out in Rule 3A.07 of the Listing Rules.

The total amount of sponsor's fee is US$500,000, of which US$nil had been paid and US$500,000 remained payable as of the Latest Practicable Date.

The Sole Sponsor has made an application on our Company's behalf to the [**REDACTED**] for the granting of the approval for the [**REDACTED**] of, and permission to [**REDACTED**], all the Shares in issue and to be [**REDACTED**] as mentioned in this document. All necessary arrangements [have been made] for the H Shares to be admitted into [**REDACTED**].

4. Compliance Advisor

Our Company has appointed Rainbow Capital (HK) Limited as our Compliance Advisor in compliance with Rule 3A.19 of the Listing Rules.

5. Preliminary Expenses

Our Company did not incur any material preliminary expenses.

6. No Material Adverse Change

Saved as disclosed in this document, our Directors confirm that there has been no material adverse change in the financial or trading position or prospects of our Group since December 31, 2025 (being the date to which the latest consolidated financial statements of our Group were prepared).

7. Promoter

The promoters of our Company are as follow:

No.	Name
1.	Aier Investment
2.	Mr. CHEN
3.	Mr. LI Li (李力)
4.	Mr. Guo Hongwei (郭宏偉)
5.	Shenzhen Dacheng Caixin Venture Capital Management Co., Ltd. (深圳市達晨財信創業投資管理有限公司)
6.	Mr. WANG Wei (萬偉)
7.	Ms. LIN Fangyu (林芳宇)

Saved as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoters in connection with the [**REDACTED**] and the related transactions described in this document.

8. Agency Fees or Commissions Received

Save as disclosed in the section headed "[**REDACTED**]" in this document, within the two years immediately preceding the date of this document, no [**REDACTED**], discounts, [**REDACTED**] or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries. Within the two years preceding the date of this document, no commission has been paid or is payable for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions, for any Shares in our Company.

9. Qualifications and Consents of Experts

The following are the qualifications of the experts who have given opinions or advice which are contained in this document:

Name	Qualification
Huatai Financial Holdings (Hong Kong) Limited	Licensed to conduct Type 1 (dealing in securities), Type 2 (dealing in future contracts), Type 3 (leverage foreign exchange trading), Type 4 (advising on securities), Type 6 (advising on corporate finance), Type 7 (providing automated trading services) and Type 9 (asset management) regulated activities as defined under the SFO
ZSZH (HK) Fuson CPA Limited	Certified Public Accountants under Professional Accountant Ordinance (Chapter 50 of the Laws of Hong Kong) and Registered Public Interest Entity Auditor under the Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Hunan Qiyuan Law Firm	Legal advisor to our Company as to PRC law
China Insights Industry Consultancy Limited	Industry consultant
Cushman & Wakefield Limited	Independent property valuer
Hylands Law Firm (Shanghai Office)	Legal advisor to our Company as to PRC data compliance law

Each of the experts named above has given and has not withdrawn its consent to the issue of this document with the inclusion of its report, letter, summary of valuations, valuation certificates and/or legal opinion (as the case may be) and references to its name included in the form and context in which it respectively appears.

Save as disclosed in this document and in connection with the [**REDACTED**] Agreements, none of the experts named above is interested legally or beneficially in any shares of any member of our Group or has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

10. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

11. Bilingual Document

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong). In case of any discrepancies between the English language version and Chinese language version of this document, the English language version shall prevail.

12. Miscellaneous

(i) Save as disclosed in "History and Corporate Structure" and in connection with the [**REDACTED**] Agreements, within the two years immediately preceding the date of this document:

(a) no share or loan capital of our Company or any of our subsidiaries has been issued nor agreed to be issued fully or partly paid either for cash or for a consideration other than cash;

(b) no commissions, discounts, brokerage fee or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries;

(c) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option; and

(d) no commission has been paid or is payable for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions of any share in our Company or any of our subsidiaries.

(ii) There are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries.

(iii) There are no arrangements under which future dividends are waived or agreed to be waived.

(iv) There are no procedures for the exercise of any right of pre-emption or transferability of subscription rights.

(v) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months immediately preceding the date this document.

(vi) There are no restrictions affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong. Our Company has no outstanding convertible debt securities or debentures.

Save for the A Shares of our Company that are listed on the Shenzhen Stock Exchange, and save for the H Shares to be issued in connection with the [**REDACTED**], none of the equity and debt securities of our Company, if any, is listed or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought).